Company Background

Stealthyx Therapeutics Ltd has been established to commercialise the intellectual property developed by Professor Yuti Chernajovsky at Barts and The London, Queen Mary's School of Medicine and Dentistry, University of London. The Company's novel delivery platform, Prothyx, is underpinned by extensive research programmes over many years, including specific work funded by the Multiple Sclerosis Society. Stealthyx has to date secured funding from the Kinetique Biomedical Seed fund and a Translational Award from the Wellcome Trust.

Stealthyx focused on the development of the Prothyx technology platform as a vehicle for drug delivery. In the first instance this was applied to protein therapeutics, which resulted in in vivo data demonstrating the ability of the platform to confer stability, latency and disease site specificity to such proteins. The investment from The Wellcome Trust allowed Stealthyx to expand the application of the Prothyx platform to include small biologically active peptides. This included work with VIP (vasoactive intestinal peptide) which Stealthyx wishes to develop in-house for both asthma and rheumatoid arthritis.

The Prothyx platform also has the potential for delivery of other molecules including siRNA and small molecules which, together with the ability to deliver proteins and peptides, gives Stealthyx a broad opportunity for partnering along with those agreements presently in place with CRT and Biogenesis Bago.

Achieved Milestones

• 2002: Stealthyx Therapeutics Ltd Founded further to securing investment from Kinetique Biomedical Seed Fund to develop Prothyx®
• 2003: Secured a translational award from Wellcome Trust to develop Prothyx® for small peptide delivery
• 2003: Initial Nature paper published, Targeting cytokines to inflammation sites. Adams et al. Nature Biotechnology, 21:1314-1320; 2003
• 2005: Secured grant funding from National Multiple Sclerosis Society (USA) and EU Integrated project FP6 to further develop the platform
• 2006: Stealthyx Therapeutics and Cancer Research Technology Announce Co-development Partnership for Tumour-targeted Therapy
• 2007: Signed an agreement with Biogenesis Bago to evaluate Prothyx® in two specific veterinary applications
• 2008 Eden Biodesign and Stealhyx Therapeutics Ltd sign deal to develop enhanced treatment for rheumatoid arthiritis.